par Gombos, Andrea 
;Barthélémy, Philippe;Awada, Ahmad
Référence Expert Opinion on Drug Metabolism & Toxicology, 11, 5, page (823-834)
Publication Publié, 2015-05
;Barthélémy, Philippe;Awada, Ahmad Référence Expert Opinion on Drug Metabolism & Toxicology, 11, 5, page (823-834)
Publication Publié, 2015-05
Article révisé par les pairs
| Résumé : | Introduction: The aberrant activation of the phosphoinositide 3-kinase-Akt-mTOR signaling pathway is a common mechanism of resistance to endocrine therapy and human epidermal growth factor receptor 2 (HER2)-targeted treatments in breast cancer. Data from large clinical trials have shown that the combination of everolimus, an orally bioavailable mTOR inhibitor with exemestane improves outcome of metastatic breast cancer resistant to non-steroidal aromatase inhibitors. On the other hand, the addition of everolimus to trastuzumab in order to overcome resistance did not show meaningful clinical benefit in recent reported Phase III clinical trials. Everolimus has a favorable pharmacokinetic (PK) profile in early breast cancer studies. The association of endocrine therapy and HER2-targeted agents did not influence the main PK parameters of the drugs.Areas covered: This review article focuses on the biological rationale of using everolimus in breast cancer and on latest advances in the field of everolimus-based combinations with an emphasis on the PK and pharmacodynamic parameters of the drug throughout different studies.Expert opinion: Better identification of patients who sustain benefit or who are resistant to everolimus-based combinations in the treatment of advanced breast cancer remains an unmet need. New combination strategies based on the understanding of resistance mechanisms and intracellular feedback loops should be studied further in the future. |
